

**CURRICULUM VITAE****INFORMAZIONI PERSONALI**

|                         |                                           |
|-------------------------|-------------------------------------------|
| Cognome e Nome          | <b>MERLANO MARCO CARLO</b>                |
| Indirizzo istituzionale | VIA M. COPPINO 26                         |
| Telefono istituzionale  | 0171616739                                |
| E-mail istituzionale    | merlano.m@ospedale.cuneo.it               |
| Amministrazione         | AZIENDA OSPEDALIERA S.CROCE E CARLE CUNEO |
| Qualifica               | MEDICO                                    |
| Incarico Aziendale      | DIRETTORE ONCOLOGIA                       |

**FORMAZIONE ED ESPERIENZA  
LAVORATIVA****TITOLI DI STUDIO**

|  |                                                                                                           |
|--|-----------------------------------------------------------------------------------------------------------|
|  | Specializzazione in oncologia (1981)<br>Presso Università degli studi di Genova<br>Con votazione 50/50L   |
|  | Laurea in medicina e chirurgia (1978)<br>Presso Università degli studi di Genova<br>Con votazione 107/110 |

**ESPERIENZA LAVORATIVA**

|  |                                                                                                                                        |
|--|----------------------------------------------------------------------------------------------------------------------------------------|
|  | Incarico di Direttore di dipartimento<br>Presso AO S.Croce & Carle Cuneo<br>Dal 2001 al 9.12.2016                                      |
|  | Incarico di Direttore Oncologia<br>Presso AO S.Croce & Carle Cuneo<br>Dal 1997 al presente                                             |
|  | Incarico di aiuto responsabile modulo degenze protette<br>Presso Istituto Nazionale per la Ricerca sul Cancro, Genova<br>(1995 – 1997) |
|  | Incarico di aiuto<br>Presso Istituto Nazionale per la Ricerca sul Cancro, Genova<br>(1990 – 1995)                                      |
|  | Incarico di assistente<br>Istituto Nazionale per la Ricerca sul Cancro, Genova<br>(1980 – 1990)                                        |

**ISTRUZIONE E FORMAZIONE**

|  |                                                                                                                                 |
|--|---------------------------------------------------------------------------------------------------------------------------------|
|  | Training formativo c/o Sidney Farber Cancer Institute, Harvard Medical School, Boston, MA, USA<br>(giugno/luglio 1980)          |
|  | Training formativo c/o Radiobiology and Biophysics unit, University of Virginia in Charlottesville, VI, USA (Marzo/Aprile 1988) |
|  | Guest Resercher c/o Medical Oncology Dept, Rush Presbyterian School of Medicine, Chicago, IL, USA<br>(Gennaio/febbraio 1989)    |

**CAPACITÀ E COMPETENZE  
PERSONALI**

|             |          |
|-------------|----------|
| MADRELINGUA | ITALIANA |
|-------------|----------|

|              |         |                 |                 |
|--------------|---------|-----------------|-----------------|
| ALTRE LINGUA |         |                 |                 |
|              | LINGUA  | Livello parlato | Livello scritto |
|              | INGLESE | BUONO           | BUONO           |

|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>PUBBLICAZIONI</b></p> | <p>AUTORE O CO-AUTORE DI CIRCA 150 ARTICOLI SU RIVISTE SCIENTIFICHE INDICIZZATE E PEER REVIEWED (SEGUE UNA SELEZIONE DEGLI ARTICOLI DEGLI ULTIMI 5 ANNI)</p> <p>A2015 – Articolo su rivista<br/> <i>Panzuto F, Rinzivillo M, Fazio N... Merlano M... Delel Fave G</i><br/> Real-world study of everolimus in advanced progressive neuroendocrine tumors<br/> (2015) <b>Oncologist</b> 20(5):570<br/> Source: PubMed</p> <p>2015 – articolo su rivista<br/> <i>Tonissi F, Lattanzio L, Merlano MC, Infante L, Lo Nigro C, Garrone O</i><br/> The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines<br/> (2015) <b>Invest New Drugs</b> May / (epub ahead of print)<br/> Source: PubMed</p> <p>2015 – articolo su rivista<br/> <i>Monteverde M, Milano G, Stroala G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C</i><br/> The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.<br/> (2015) <b>Critical Rev Oncol Hematol</b> 10.1016/j.critrevonc.2015.02.014<br/> Source: PubMed</p> <p>2015 – articolo su rivista<br/> <i>Mirabile A, Numico G, Russi EG... Merlano MC... Dellinger RP</i><br/> Sepsis in head and neck cancer patients treated with chemotherapy and radioation: Literature review and consensus<br/> (2015) <b>Critical Rev Oncol Hematol</b><br/> doi:10.1016/j.critrevonc.2015.03.003<br/> Source: PubMed</p> <p>2015 – Articolo su rivista<br/> <i>Garrone O, Bertelli G, Principe E, Lewis PD, Occelli M, Miraglio E, Merlano MC</i><br/> A prospective randomized study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.<br/> (2014) <b>Tumori</b> 100(6):620-4<br/> Source: PubMed</p> <p>2015 – Articolo su rivista<br/> <i>Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi EG, Milano G, Merlano M, Lo Nigro C.</i><br/> Treatment effect of buparlisib, cetuximab, and irradiation in wild-type or PI3KCA-mutated head and neck cancer lines.<br/> (2015) <b>Invest New Drugs</b> 33(2):310-20<br/> Source: PubMed</p> <p>2015 – Articolo su rivista<br/> <i>Mesia R, Henke M, Fortin A...Merlano MC... Girault J.</i><br/> Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (CONCERT-1): a randomized, controlled, open-label phase II trial<br/> (2015) <b>Lancet Oncol</b> 33(2):208-20<br/> Source: PubMed</p> <p>2015 – Articolo su rivista<br/> <i>Lattanzio L, Borgognone M, Mocellini C, Giordano F, ... Merlano MC, Lo Nigro C.</i><br/> MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.<br/> (2015) <b>Int J Biol Markers</b> 30(2):e208-16<br/> Source: PubMed</p> |
|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

2014 – Articolo su rivista  
*Denaro N, Merlano MC, Russi EG, Lo Nigro C*  
 Non Coding RNAs in head and neck squamous cell carcinoma (HNSCC): a clinical perspective.  
 (2014) **Anticancer Res** 34(12):68867-96  
 Source: PubMed

2014 – Articolo su rivista  
*Panzuto F, Rinzivillo M, Fazio N... Merlano MC...Delle Fave G*  
 Real-world study of everolimus in advanced progressive neuroendocrine tumors.  
 (2014) **Oncologist** 19(9):966-974  
 Source: PubMed

2014 – articolo su rivista  
*Denaro N, Russi EG, Adamop V, Merlano MC*  
 State-of the-art and emerging treatment options in the management of head and neck cancer: news from 2013.  
 (2014) **Oncology** 86(4):212-229  
 Source: PubMed

2014 – Articolo su rivista  
*Messa F, Tonissi F, Millo E, Bracco E, Ungari S, Lattanzio L, Merlano M, Damonte G, Lo Nigro C*  
 A PNA-Mediated clamping PCR for routine detection of Kras mutations in colorectal carcinoma.  
 (2014) **Int. J Biol Markers** 29(1):e55-61  
 Source: PubMed

2013 – Articolo su rivista  
*Denaro N, Nigro CL, Russi EG, Merlano MC*  
 The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer  
 (2013) **Onco Targets Ther** 16(9):1231-1241  
 Source: PubMed

2013 – Articolo su rivista  
*Denaro N, Russi EG, Merlano MC*  
 Strategies for non-resectable head and neck cancer  
 (2013) **Curr Treat Options Oncol.** 14(4):492-504  
 Source: PubMed

2013 – Articolo su rivista  
*Vivenza D, Feola M, Garrone O, Monteverde M, Merlano MC, Lo Nigro C.*  
 Role of Renin-angiotensin-aldosterone system and the glutathioneS-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.  
 (2013) **Int. J. Biol. Markers** 28(4):e336-47  
 Source: PubMed

2013 – lettera su rivista  
*Russi EG, Numico G, Merlano MC*  
 Non-surgical conservative approach for laringea cancer: what information should patients be given?  
 (2013) **J. Clin. Oncol.** 31(25):3168-70  
 Source: PubMed

2013 – articolo su rivista  
*Guérin, O., Etienne-Grimaldi, M.-C., Monteverde, M., Sudaka, A., Brunstein, M.-C., Formento, P., Lattanzio, L., Maffi, M., Tonissi, F., Ortholan, C., Pagès, G., Fischel, J.-L., Lo Nigro, C., Merlano, M., Milano, G.*  
 Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>(2013) <b>Urologic Oncology</b>: Seminars and Original Investigations, 31 (8), pp. 1567-1575.<br/> Document Type: Article<br/> Source: Scopus<br/> Impact Factor (I.F.) 3.647</p> <p>2013 – articolo su rivista<br/> <i>Denaro, N., Russi, E.G., Lefebvre, J.L., Merlano, M.C.</i><br/> A systematic review of current and emerging approaches in the field of larynx preservation</p> <p>(2014) <b>Radiotherapy and Oncology</b>, . Article in Press.<br/> Document Type: Article in Press<br/> Source: Scopus<br/> I.F. 4.520</p> <p>2013 – articolo su rivista<br/> <i>Lattanzio, L., Tonissi, F., Torta, I., Gianello, L., Russi, E., Milano, G., Merlano, M., Lo Nigro, C.</i><br/> Role of IL-8 induced angiogenesis in uveal melanoma</p> <p>(2013) <b>Investigational New Drugs</b>, 31 (5), pp. 1107-1114.<br/> Document Type: Article<br/> Source: Scopus<br/> I.F. 3.498</p> <p>2013 – articolo su rivista<br/> <i>Russi, E.G., Bensadoun, R.-J., Merlano, M.C., Bourhis, J., Ricardi, U., Giralt, J., Pinto, C., Budach, W., Corvò, R., Lacouture, M.E., Bernier, J.</i><br/> Bio-radiation dermatitis: The need of a new grading: In regard to Bernier et al: Ann Oncol 2011; 22 (10): 2191-2200</p> <p>(2013) <b>Annals of Oncology</b>, 24 (9), art. no. mdt281, pp. 2463-2465.<br/> Document Type: Letter<br/> Source: Scopus<br/> I.F. 7.384</p> <p>2013 – articolo su rivista<br/> <i>Denaro, N., Merlano, M.C., Russi, E.G.</i><br/> Dysphagia in head and neck cancer patients: Pretreatment evaluation, predictive factors, and assessment during radio-chemotherapy, recommendations</p> <p>(2013) <b>Clinical and Experimental Otorhinolaryngology</b>, 6 (3), pp. 117-126.<br/> Document Type: Review<br/> Source: Scopus<br/> I.F. 1.13</p> <p>2013 – articolo su rivista<br/> <i>Monteverde, M., Tonissi, F., Fischel, J.-L., Etienne-Grimaldi, M.-C., Milano, G., Merlano, M., Lo Nigro, C.</i><br/> Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line</p> <p>(2013) <b>Urologic Oncology: Seminars and Original Investigations</b>, 31 (6), pp. 776-786.<br/> Document Type: Article<br/> Source: Scopus<br/> I.F. 3.647</p> <p>2013 – articolo su rivista<br/> <i>Nigro, C.L., Wang, H., McHugh, A., Lattanzio, L., Matin, R., Harwood, C., Syed, N., Hatzimichael, E., Briasoulis, E., Merlano, M., Evans, A., Thompson, A., Leigh, I., Fleming, C., Inman, G.J., Proby, C., Crook, T.</i><br/> Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma</p> <p>(2013) <b>Journal of Investigative Dermatology</b>, 133 (5), pp. 1278-1285. Cited 2 times.<br/> Document Type: Article</p> |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>Source: Scopus<br/>I.F. 6.193</p> <p>2013 - articolo su rivista<br/><i>Lattanzio, L., Tonissi, F., Monteverde, M., Milano, G., Merlano, M.C., Lo Nigro, C.</i><br/>Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel resistance status in PC3 prostate cancer cells<br/>(2013) <b>Anti-Cancer Drugs</b>, 24 (2), pp. 120-130.<br/>Document Type: Article<br/>Source: Scopus<br/>I.F. 2.232</p> <p>2013 - articolo su rivista<br/><i>Sudaka, A., Susini, A., Lo Nigro, C., Fischel, J.-L., Toussan, N., Formento, P., Tonissi, F., Lattanzio, L., Russi, E., Etienne-Grimaldi, M.C., Merlano, M., Milano, G.</i><br/>Combination of bevacizumab and irradiation on uveal melanoma: An in vitro and in vivo preclinical study<br/>(2013) <b>Investigational New Drugs</b>, 31 (1), pp. 59-65. Cited 1 time.<br/>Document Type: Article<br/>Source: Scopus<br/>I.F. 3.498</p> <p>2013 - Articolo in rivista<br/><i>Denaro, N., Russi, E.G., Numico, G., Pazzia, T., Vitiello, R., Merlano, M.C.</i><br/>The role of neck dissection after radical chemoradiation for locally advanced head and neck cancer: Should we move back?<br/>(2013) <b>Oncology</b> (Switzerland), 84 (3), pp. 174-185.<br/>Document Type: Article<br/>Source: Scopus<br/>I.F. 2.112</p> <p>2012 - Articolo in rivista<br/><i>Palmieri c, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, LoNigro C, Merlano M, Crook T (2012).</i><br/>Site-specific CpG Methylation in the CCAAT/enhancer binding protein delta (CEBP)CpG island in breast cancer is associated with metastatic relapse.<br/><b>BRITISH JOURNAL OF CANCER</b>,<br/>ISSN: 0007-0920</p> <p>2012 - Articolo in rivista<br/><i>Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, LoNigro C, Merlano M, Crook T (2012).</i><br/>Methylation of the calcium channel regulatory subunit A2D-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.<br/><b>BRITISH JOURNAL OF CANCER</b>, ISSN: 0007-0920</p> <p>2012 - Articolo in rivista<br/><i>Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Merlano M, LoNigro C (2012).</i><br/>MDM 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.<br/><b>ORAL ONCOLOGY</b>, ISSN: 1368-8375</p> <p>2012 - Articolo in rivista<br/><i>Denaro N, Russi EG, Colantonio I, Adamo V, Merlano M (2012).</i><br/>The role of antiangiogenic agents in the treatment of head and neck cancer.<br/><b>ONCOLOGY</b>, ISSN: 0030-2414</p> <p>2012 - Articolo in rivista<br/><i>LoNigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, Garrone O, Merlano M, Crook T (2012).</i></p> |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>NT5E CpG island methylation is a favourable breast cancer biomarker. <b>BRITISH JOURNAL OF CANCER</b>, ISSN: 0007-0920</p> <p>2012 - Articolo in rivista<br/> <i>Sudaka A, Susini A, LoNigro C, Fischel J-L, Toussan N, Formento P, Tonissi F, Occelli M, Merlano M, Milano G (2012).</i><br/> Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.<br/> <b>INVESTIGATIONAL NEW DRUGS</b>, ISSN: 0167-6997</p> <p>2012 - Articolo in rivista<br/> <i>Garrone O, Crosetto N, LoNigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M (2012).</i><br/> Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.<br/> <b>CARDIOVASCULAR TOXICOLOGY</b>, ISSN: 1530-7905</p> <p>2012 - Articolo in rivista<br/> <i>Bracarda S, Ruggeri EM, Monti M, Merlano M, D'Angelo A, Ferraù F, Cortesi E, Santoro A (2012).</i><br/> Early detection, prevention and management of cutaneous adverse events due to sorafenib:<br/> Recomandations from the sorafenib Working Group.<br/> <b>CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY</b>, ISSN: 1040-8428</p> <p>2012 - Articolo in rivista<br/> <i>Merlano M, Monteverde M, Colantonio I, Denaro N, LoNigro C, Natoli G, Giurlasda F, (...), Russi E (2012).</i><br/> Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer.<br/> <b>ORAL ONCOLOGY</b>, vol. 48, ISSN: 1368-8375</p> <p>2012 - Articolo in rivista<br/> <i>Guerin E, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Merlano M, (...), Milano G (2012).</i><br/> Contrasted effects of the multitarget TKI vandetanib on docetaxel sensitive and docetaxel resistant prostate cancer cell lines.<br/> <b>UROLOGIC ONCOLOGY</b>, ISSN: 1078-1439</p> <p>2012 - Articolo in rivista<br/> <i>Russi EG, Corvò R, Merlotti A, Alterio D, Franco P, Pergolizzi S, De Sanctis V, Merlano M, (...) Bernier J (2012).</i><br/> Swallowing disfunction in head and neck cancer patients treated by radiotherapy: Review and recommendations of supportive task group of the Italian Association of Radiation Oncology. <b>CANCER TREATMENT REVIEWS</b>, ISSN: 0305-7372</p> <p>2012 - Articolo in rivista<br/> <i>Wang H, Lee S, LoNigro C, Lattanzio L, Merlano M, Monteverde M, Marin R, Occelli M, (...), Crook T (2012).</i><br/> NT5E (CD 73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.<br/> <b>BRITISH JOURNAL OF CANCER</b>, ISSN: 0007-0920</p> <p>2012 - Articolo in rivista<br/> <i>LoNigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, (...) Crook T (2012).</i><br/> High frequency of complex TP53 mutations in CNS metastases from breast cancer.<br/> <b>BRITISH JOURNAL OF CANCER</b>, ISSN: 0007-0920</p> <p>2012 - Articolo in rivista<br/> <i>Russi EG, Merlano M, Numico G, Corvò R, Benasso M, Vigna-Taglianti R, Melano A, (...) Ricardi U (2012).</i><br/> The effects of pain and activity of the daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy.</p> |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**SUPPORTIVE CARE IN CANCER, ISSN: 0941-4355**

2012 - Articolo in rivista

*Guerin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, (...), Merlano M, Milano G (2012).*

Contrasted effects of the multitarget TKI vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

**UROLOGIC ONCOLOGY, ISSN: 1078-1439**

2012 - Articolo in rivista

*Hatzimichael, E., Lo Nigro, C., Lattanzio, L., Syed, N., Shah, R., Dasoula, A., Janczar, K., Vivenza, D., Monteverde, M., Merlano M, Papoudou-Bai, A., Bai, M., Schmid, P., Stebbing, J., Bower, M., Dyer, M.J.S., Karran, L.E., Elguetakarstegl, C., Farrell, P.J., Thompson, A., Briasoulis, E., Crook, T. (2012).*

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. **BRITISH JOURNAL OF CANCER, ISSN: 0007-0920**

2012 - Articolo in rivista

*Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano M, Lo Nigro C. (2012).*

Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells.

**ANTI-CANCER DRUGS, ISSN: 1473-5741**

2012 - Articolo in rivista

*Fallowfield LJ, Kilburn LS, Langridge C, Snowden CF, Bliss JM, Coombes RC, IES Trial Steering Committee, Merlano M (2012).*

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.

**BRITISH JOURNAL OF CANCER, ISSN: 0007-0920**

2012 - Articolo in rivista

*Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ, IES Steering Committee, Merlano M (2012).*

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early

breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

**LANCET ONCOLOGY, ISSN: 1470-2045**

2011 - Articolo in rivista

*Numico G, Occelli M, Russi EG, Silvestris N, Pasero R, (...), Merlano M (2011).*

Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score.

**SUPPORTIVE CARE IN CANCER, ISSN: 0941-4355**

2011 - Articolo in rivista

*Bernier J, Russi EG, Homey B, Merlano M, Mesia R, Peyrade F, Budach W (2011).*

Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposal for a revised grading system and consensus management guidelines.

**ANNALS OF ONCOLOGY, ISSN: 0923-7534**

2011 - Articolo in rivista

*Denaro N, Russi EG, Adamo V, Colantonio I, Merlano M (2011).*

Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions.

**ONCOLOGY, ISSN: 0030-2414**

2011 - Articolo in rivista

*Feola M, Garrone O, Occelli m, Francini A, Biggi A, Visconti G, (...), Merlano M (2011).*

Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin and brain natriuretic peptide.

**INTERNATIONAL JOURNAL OF CARDIOLOGY, ISSN: 0167-5273**

2011 - Articolo in rivista

*Pinto C, Barone CA, Girolimoni G, Russi EG, Merlano M, Ferrais D, Maiello E (2011).*

Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p><b>THE ONCOLOGIST</b>, ISSN: 1083-7159</p> <p>2011 - Articolo in rivista<br/> <i>Russi EG, Numico G, Merlano M, Pinto C (2011).</i><br/> cetuximab related radiation dermatitis in head and neck cancer patients: in regard to Suder et al.<br/> <b>INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS</b>, ISSN: 0360-3016</p> <p>2011 - Articolo in rivista<br/> <i>Merlano M, Russi EG, Benasso M, (...), Garrone O (2011).</i><br/> Cisplatin based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.<br/> <b>ANNALS OF ONCOLOGY</b>, ISSN: 0923-7534</p> <p>2011 - Contributo in volume (Capitolo o Saggio)<br/> <i>Locati L.D., Merlano M (2011).</i><br/> Terapia medica integrata nei carcinomi squamocellulari. In: tumori della testa e del collo. <b>Springer Ed..</b></p> <p>2010 - Articolo in rivista<br/> <i>LoNigro C, Monteverde M, Riba M, Latanzio L Garrone O, (...), Merlano M (2010).</i><br/> Espressione profiling and long lasting responses to chemotherapy in metastatic gastric cancer.<br/> <b>INTERNATIONAL JOURNAL OF ONCOLOGY</b>, ISSN: 1019-6439</p> <p>2010 - Articolo in rivista<br/> <i>Loupakis F, Masi G, Fornaro L, Vasile E (...), Merlano M, Falcone A (2010).</i><br/> Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.<br/> <b>CANCER CHEMOTHERAPY AND PHARMACOLOGY</b>, ISSN: 0344-5704</p> <p>2010 - Articolo in rivista<br/> <i>Caponigro F, Lorusso D, Fornari G, Barone C, Merlano M, (...), Comis S (2010).</i><br/> Phase I dose escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.<br/> <b>CANCER CHEMOTHERAPY AND PHARMACOLOGY</b>, ISSN: 0344-5704</p> <p>2010 - Articolo in rivista<br/> <i>Numico G, Russi EG, Colantonio I, (...), Merlano M (2010).</i><br/> EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy.<br/> <b>ANTICANCER RESEARCH</b>, ISSN: 0250-7005</p> <p>2010 - Contributo in volume (Capitolo o Saggio)<br/> <i>Merlano M, Garrone O (2010).</i><br/> Tumori del distretto cervico-facciale. In: Oncologia Medica Pratica<br/> <b>Società Editrice Universo Ed..</b></p> <p>UTORI, TITOLO, DOVE PUBBLICATO, QUANDO</p> |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Data di ultimo aggiornamento: 30/12/2016